SPIRONOLACTONE

被引：77

作者：

OCHS, HR

GREENBLATT, DJ

BODEM, G

SMITH, TW

机构：

[1] MASSACHUSETTS GEN HOSP,DEPT MED,CLIN PHARMACOL UNIT,BOSTON,MA 02114

[2] PETER BENT BRIGHAM HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115

[3] HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115

[4] UNIV BONN,MED KLIN,D-5300 BONN 1,FED REP GER

来源：

AMERICAN HEART JOURNAL | 1978年 / 96卷 / 03期

关键词：

D O I：

10.1016/0002-8703(78)90052-2

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：389 / 400

页数：12

共 200 条

[31] SUPPRESSION BY SPIRONOLACTONE METABOLITE CANRENONE OF PLASMA TESTOSTERONE IN MAN [J].

ERBLER, HC .

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1974, 285 (04) :403-406

[32] EFFECT OF ALDOSTERONE ANTAGONIST CANRENONE ON PLASMA ALDOSTERONE CONCENTRATION AND PLASMA-RENIN ACTIVITY, AND ON EXCRETION OF ALDOSTERONE AND ELECTROLYTES BY MAN [J].

ERBLER, HC ;

WERNZE, H ;

HILFENHAUS, M .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1976, 9 (04) :253-257

[33] SELECTIVE-INHIBITION OF ALDOSTERONE SYNTHESIS BY 11-HYDROXYLATED SPIROLACTONE IN RAT ADRENALS [J].

ERBLER, HC .

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1973, 280 (03) :331-337

[34]

FALOON WW, 1960, CLIN USE ALDOSTERONE, P115

[35] USE OF SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE IN TREATMENT OF OEDEMA [J].

FARRELLY, RO ;

HOWIE, RN ;

NORTH, JDK .

BRITISH MEDICAL JOURNAL, 1960, 2 (JUL30) :339-343

[36] INTERACTIONS OF SPRIONOLACTONE WITH HEPATIC MICROSOMAL DRUG-METABOLIZING ENZYME SYSTEMS [J].

FELLER, DR ;

GERALD, MC .

BIOCHEMICAL PHARMACOLOGY, 1971, 20 (08) :1991-&

[37]

FELLER DR, 1971, P SOC EXP BIOL MED, V136, P1347

[38]

FERLINZ R, 1969, MED WELT STUTTG, V20, P1751

[39] MOLECULAR MODIFICATIONS OF ANTI-ALDOSTERONE COMPOUNDS - EFFECTS ON AFFINITY OF SPIRONOLACTONES FOR RENAL ALDOSTERONE RECEPTORS [J].

FUNDER, JW ;

FELDMAN, D ;

HIGHLAND, E ;

EDELMAN, IS .

BIOCHEMICAL PHARMACOLOGY, 1974, 23 (10) :1493-1501

[40]

GANTT CL, 1962, LANCET, V1, P1130

← 1 2 3 4 5 6 7 8 9 10 →